BUND FINANCE › Stocks › WST
West Pharmaceutical Services, Inc. (WST)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:01 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +5.42% above its 50-day average.
- It is +25.00% above its 200-day average (long-term uptrend).
- It sits at 84% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$2.8B | US$2.9B | US$3.0B | US$2.9B | US$3.1B |
| Net income | US$661.8M | US$585.9M | US$593.4M | US$492.7M | US$493.7M |
| EPS (diluted) | 8.67 | 7.73 | 7.88 | 6.69 | 6.80 |
| Gross margin | 41.5% | 39.5% | 38.4% | 34.7% | 35.9% |
| Operating margin | 26.8% | 26.5% | 24.1% | 20.6% | 20.1% |
| Net margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| Free cash flow | US$330.6M | US$439.4M | US$414.5M | US$276.4M | US$468.9M |
| Total debt | US$325.3M | US$317.9M | US$309.0M | US$305.3M | US$416.7M |
| Cash | US$762.6M | US$894.3M | US$853.9M | US$484.6M | US$791.3M |
Compound annual growth: revenue 2.1% · net income -7.1% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 45.3x | 43.1x | 27.1x |
| EV / EBITDA | 28.9x | 29.5x | 16.5x |
| Operating margin | 23.0% | — | 3.6% |
| Net margin | 18.8% | — | -0.0% |
| Debt / equity | 0.37 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice